Supriya Lifescience has scheduled its 18th Annual General Meeting (AGM) for Thursday, September 24, 2026. The meeting will be conducted through Video Conferencing or Other Audio Video Means (OAVM). The Board of Directors recommended a final dividend of Re. 1.00 per equity share for FY26 during its meeting on May 27, 2026. This proposal is subject to shareholder ratification at the AGM.

The company has also intimated the weblink for the Annual Report and AGM notice for FY26. Shareholders can access the soft copy of the Annual Report and the Notice convening the 18th AGM via the path provided on the company’s website. Physical copies were sent to shareholders who have not registered their email addresses with the company, depositories, or the Registrar and Transfer Agent (RTA), MUFG Intime India Pvt. Ltd., as on the cut-off date of August 21, 2026.

Financial Performance

FY26 marked the company's highest-ever annual revenue and EBITDA. Revenue from operations grew 18.9% year-on-year to ₹8,278.75 crore. Profit after tax increased 11.2% to ₹2,091.20 crore. EBITDA rose 12.8% to ₹294.1 crore, with margins at 35.5%. The company delivered strong demand across core therapeutic segments, supported by backward integration and disciplined execution.

Business Responsibility & Sustainability Report

The company released its fourth Business Responsibility and Sustainability Report (BRSR) for FY26. Key operational highlights include:

• Global Reach: Exports account for 82% of total turnover, with the company serving customers in 128 countries.
• Workforce: Total employees stood at 1,310. The board comprises 40% women, while key management personnel include 50% women.
• Safety: The company reported zero lost-time injuries and zero fatalities in FY26.
• Environmental: Total energy consumption was 223,789.94 GJ. Scope 1 and Scope 2 greenhouse gas emissions intensity decreased to 1.89 TCO2e per million rupees of turnover, down from 2.00 TCO2e in FY25.
• Waste Management: Total waste generated increased to 884.69 metric tonnes from 87.71 metric tonnes in the previous year, largely driven by construction and demolition waste.

Dividend Details

The final dividend will be paid within 30 days of the AGM, provided it receives member approval. Eligibility is determined by the names appearing in the Register of Members as on the record date of September 4, 2026. The dividend payout represents an outflow of ₹80.48 million.

Strategic Updates

Backward-integrated products accounted for 76% of revenue, supporting cost competitiveness. The company successfully completed an unannounced USFDA inspection at its Lote facility in February 2026, receiving its Establishment Inspection Report with one minor observation. Capital expenditure of ₹152 crore was directed largely towards the Ambernath facility, which extends manufacturing into formulations and contract manufacturing.

Board Re-appointments

Shareholders will vote on the re-appointment of Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh, who retire by rotation. Dr. Saloni Wagh serves as Managing Director, overseeing export, marketing, and business development. She holds a PhD in Chemistry and has been associated with the company since 2014. Ms. Shivani Wagh serves as Joint Managing Director, focusing on exports to Europe. She holds a master's degree in international business management from the University of Manchester. Both directors attended four board meetings in FY25-26 and hold 1,02,375 shares each (0.13%).

Special Business

The AGM agenda includes ratifying the remuneration of Cost Auditors for FY 2026-27. The Board appointed M/s. Rampurawala Mohammed A & Co as Cost Auditors for a fee of ₹2.50 lakh plus applicable tax and out-of-pocket expenses. This appointment is subject to shareholder approval via an ordinary resolution.

Supriya Lifescience Limited stated that judicial proceedings involving its General Manager – Sales & Marketing remain sub judice. The company disclosed this update to stock exchanges on September 2, 2026.

The matter is currently awaiting hearing and adjudication before the Hon'ble Court of Law. No further development or order has been passed by the court as on date.

Regulatory Disclosure

This update references an earlier intimation dated July 4, 2026, submitted pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed investors of the case status during its earnings call and through transcripts submitted to stock exchanges on August 14, 2026, and August 18, 2026, respectively.

Supriya Lifescience confirmed it will continue to monitor the matter. The company will inform the stock exchanges of any material development or court order as received, in accordance with applicable regulatory requirements.